GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gemina Laboratories Ltd (XCNQ:GLAB) » Definitions » EV-to-EBIT

Gemina Laboratories (XCNQ:GLAB) EV-to-EBIT : -5.45 (As of May. 27, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Gemina Laboratories EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Gemina Laboratories's Enterprise Value is C$33.33 Mil. Gemina Laboratories's EBIT for the trailing twelve months (TTM) ended in Oct. 2023 was C$-6.12 Mil. Therefore, Gemina Laboratories's EV-to-EBIT for today is -5.45.

The historical rank and industry rank for Gemina Laboratories's EV-to-EBIT or its related term are showing as below:

XCNQ:GLAB' s EV-to-EBIT Range Over the Past 10 Years
Min: -26.36   Med: 0   Max: 0
Current: -5.45

XCNQ:GLAB's EV-to-EBIT is ranked worse than
100% of 424 companies
in the Biotechnology industry
Industry Median: 10 vs XCNQ:GLAB: -5.45

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Gemina Laboratories's Enterprise Value for the quarter that ended in Oct. 2023 was C$34.96 Mil. Gemina Laboratories's EBIT for the trailing twelve months (TTM) ended in Oct. 2023 was C$-6.12 Mil. Gemina Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Oct. 2023 was -17.50%.


Gemina Laboratories EV-to-EBIT Historical Data

The historical data trend for Gemina Laboratories's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gemina Laboratories EV-to-EBIT Chart

Gemina Laboratories Annual Data
Trend Jan21 Jan22 Jan23
EV-to-EBIT
- -5.64 -7.73

Gemina Laboratories Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -5.35 -7.73 -6.46 -5.68 -5.72

Competitive Comparison of Gemina Laboratories's EV-to-EBIT

For the Biotechnology subindustry, Gemina Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gemina Laboratories's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gemina Laboratories's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Gemina Laboratories's EV-to-EBIT falls into.



Gemina Laboratories EV-to-EBIT Calculation

Gemina Laboratories's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=33.328/-6.117
=-5.45

Gemina Laboratories's current Enterprise Value is C$33.33 Mil.
Gemina Laboratories's EBIT for the trailing twelve months (TTM) ended in Oct. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-6.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gemina Laboratories  (XCNQ:GLAB) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Gemina Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Oct. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Oct. 2023 ) =EBIT / Enterprise Value (Q: Oct. 2023 )
=-6.117/34.963173
=-17.50 %

Gemina Laboratories's Enterprise Value for the quarter that ended in Oct. 2023 was C$34.96 Mil.
Gemina Laboratories's EBIT for the trailing twelve months (TTM) ended in Oct. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-6.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gemina Laboratories EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Gemina Laboratories's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Gemina Laboratories (XCNQ:GLAB) Business Description

Traded in Other Exchanges
Address
3800 Gilmore Mall, Suite 302, Burnaby, BC, CAN, V5G 4R8
Gemina Laboratories Ltd is a biotechnology company that operates in the In Vitro Diagnostics (IVD) market under the name Gemina Labs. The company endeavors to develop novel surface functionalization chemistries for the detection of pathogens and biomarkers.

Gemina Laboratories (XCNQ:GLAB) Headlines

No Headlines